Themis Medicare Limited

NSE THEMISMED.NS

Themis Medicare Limited Free Cash Flow Yield on February 06, 2025: 0.18%

Themis Medicare Limited Free Cash Flow Yield is 0.18% on February 06, 2025, a 129.00% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Themis Medicare Limited 52-week high Free Cash Flow Yield is 0.21% on June 04, 2024, which is 19.89% above the current Free Cash Flow Yield.
  • Themis Medicare Limited 52-week low Free Cash Flow Yield is -0.70% on February 12, 2024, which is -496.02% below the current Free Cash Flow Yield.
  • Themis Medicare Limited average Free Cash Flow Yield for the last 52 weeks is 0.06%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
SV Wall Street
NSE: THEMISMED.NS

Themis Medicare Limited

CEO Dr. Sachin Dinesh Patel CChem., Ph.D.
IPO Date April 2, 2007
Location India
Headquarters 11/12 Udyog Nagar Industrial Estate
Employees 1,509
Sector Healthcare
Industries
Description

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, including anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was incorporated in 1969 and is headquartered in Mumbai, India.

Similar companies

SMSPHARMA.NS

SMS Pharmaceuticals Limited

USD 2.47

1.65%

RPGLIFE.NS

RPG Life Sciences Limited

USD 28.88

1.88%

TIIL.NS

Technocraft Industries (India) Limited

USD 30.69

1.36%

GUFICBIO.NS

Gufic Biosciences Limited

USD 4.85

-1.12%

VENUSREM.NS

Venus Remedies Limited

USD 4.02

-0.10%

StockViz Staff

February 7, 2025

Any question? Send us an email